Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the n...
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
- Conditions
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 900
- Registration Number
- NCT05984277
- Locations
- 🇬🇧
Research Site, Truro, United Kingdom
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Loyola University
- Target Recruit Count
- 40
- Registration Number
- NCT05983276
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
- Conditions
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05977998
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- wang shusen
- Target Recruit Count
- 116
- Registration Number
- NCT05978648
- Locations
- 🇨🇳
Sun-yat sen university cancer center, Guangzhou, Gangdong, China
Role of Curcumin in Paclitaxel Induced PN
- Conditions
- Interventions
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 80
- Registration Number
- NCT05966441
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 2400
- Registration Number
- NCT05929768
- Locations
- 🇺🇸
Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Cancer Center of Kansas-Independence, Independence, Kansas, United States
Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- NorthShore University HealthSystem
- Target Recruit Count
- 170
- Registration Number
- NCT05921149
- Locations
- 🇺🇸
NorthShore University HealthSystem, Evanston, Illinois, United States
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Akeso
- Target Recruit Count
- 233
- Registration Number
- NCT05904379
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 132
- Registration Number
- NCT05900921
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Karolinska University Hospital
- Target Recruit Count
- 370
- Registration Number
- NCT05900206
- Locations
- 🇸🇪
Stockholm Southern Hospital, Stockholm, Sweden
🇸🇪Skåne University Hospital, Malmö, Sweden
🇸🇪Sankt Gorans Hospital, Stockholm, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.